WaveMan
WaveMan · Company
HEPA · Hepion Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

HEPA Hepion Pharmaceuticals (HEPA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001583771
Quote by TradingView
Cluster · 6 insidersActivist 13DC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about HEPA

Insiders, 180 days
+$835.0K net bought
6 buyers
Activist stakes (13D), 180 days
5 filings
Largest: 21.5% of the class

Hepion Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Hepion Pharmaceuticals, Inc. insiders bought a net $835.0K of stock across 20 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Fisher Danina
Director
BUY
2026-10-02 SECtraded 2026-09-29
200,000
$10.0K
+20.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 200,000 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fisher Danina bought about $10.0K of HEPA on Sep 29, 2026.
LoPriore Vincent S
Executive Chairman
BUY
2026-08-12 SECtraded 2026-08-03
8,000,000
$400.0K
+71.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 21, 2026.
  • The trade is 56.1% of the 14,250,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman LoPriore Vincent S bought about $400.0K of HEPA on Aug 3, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days.
LoPriore Vincent S
Executive Chairman
BUY
2026-08-12 SECtraded 2026-08-03
2,000,000
$100.0K
+71.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 21, 2026.
  • The trade is 12.3% of the 16,250,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman LoPriore Vincent S bought about $100.0K of HEPA on Aug 3, 2026; 4 other insiders bought within 30 days.
Appajosyula Sireesh
Chief Operating Officer
BUY
2026-08-12 SECtraded 2026-08-03
2,000,000
$100.0K
+71.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 21, 2026.
  • The trade is 61.5% of the 3,250,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Appajosyula Sireesh bought about $100.0K of HEPA on Aug 3, 2026; 4 other insiders bought within 30 days.
Purcell Michael J.
Director
BUY
2026-08-12 SECtraded 2026-08-03
2,000,000
$100.0K
+71.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 21, 2026.
  • The trade is 61.5% of the 3,250,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Purcell Michael J. bought about $100.0K of HEPA on Aug 3, 2026; 4 other insiders bought within 30 days.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 15 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$835.0K over 180 days
+$835.0K over 90 days
more than 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 93% of Pharma & Biotech
The situation: each line is one rule over one dataset
Gravitas Collective Corp. disclosed a 5%+ stake (19.9%) in the last six months.
What changed in the last 30 days
Oct 26Gravitas Collective Corp. filed a 13D for 19.9%
Oct 2Director Fisher Danina bought $10.0K (Sep 29)

Watch HEPA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+76.6%12M
-49%+3%+54%+106%2025-102025-122026-022026-042026-062026-082026-10 2026-08-03 · LoPriore Vincent S bought $400.0K2026-04-21 · LoPriore Vincent S bought $200.0K2026-08-03 · LoPriore Vincent S bought $100.0K2026-08-03 · Appajosyula Sireesh bought $100.0K2026-08-03 · Purcell Michael J. bought $100.0K2026-08-03 · Stetz Gary S. bought $100.0K2026-04-21 · Purcell Michael J. bought $50.0K2026-04-21 · LoPriore Vincent S bought $50.0K2026-04-21 · Appajosyula Sireesh bought $50.0K2026-04-21 · Stetz Gary S. bought $50.0K2026-08-03 · Stetz Gary S. II bought $25.0K2026-09-29 · Fisher Danina bought $10.0K2026-10-26 · Gravitas Collective Corp. filed a 5%+ stake (19.9%)2026-08-20 · Sireesh Appajosyula filed a 5%+ stake (5.7%)2026-08-20 · Gary Stetz filed a 5%+ stake (5.7%)2026-08-07 · Black Global 5 LLC filed a 5%+ stake (11.1%)2026-08-07 · Red Global 3, LLC filed a 5%+ stake (11.1%)2026-08-07 · Darin Feinstein filed a 5%+ stake (11.1%)2026-05-01 · Gravitas Capital LP filed a 5%+ stake (17.17%)2026-05-01 · Invictus Capital Advisors Pension Plan filed a 5%+ stake (4.29%)2026-05-01 · Vincent LoPriore filed a 5%+ stake (21.46%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns HEPA: institutional holders (13F)

13F holdings, latest reported quarter
Ancora Advisors LLC
1 sh
$0

Congress trades in HEPA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Gravitas Collective Corp.
Activist 13D · 2026-10-26
19.9%
Sireesh Appajosyula
Activist 13D · 2026-08-20
5.7%
Gary Stetz
Activist 13D · 2026-08-20
5.7%
Black Global 5 LLC
Activist 13D · 2026-08-07
11.1%
Red Global 3, LLC
Activist 13D · 2026-08-07
11.1%

HEPA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
1
Early Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $835.0K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

HEPA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2023-04-01 to 2024-03-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$1.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.14x
current debt only, 2021-03-31 (63 months older than the period end); equity 2026-06-30
Cash flow to debt
-9.03x
TTM operating cash flow over current debt only, 2021-03-31 (63 months older than the period end)
Return on equity
-125.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-99.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-117.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$2.9M
market value at close 2026-10-27 on 2026-08-10 shares, plus current debt only, 2021-03-31 (63 months older than the period end), minus cash 2019-12-31
FCF yield
-14.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$0$0
Operating income-$4.2M-$19.3M-$48.4M-$45.5M
Net income-$8.3M-$13.2M-$48.9M-$42.2M
EPS (diluted)-0.88-107.35-616.07-11.90
Operating cash flow-$3.3M-$18.2M-$40.9M-$35.0M
SEC XBRL, fiscal years, as known on 2026-10-28

HEPA Stock Sonar score 4/7 axes

Find similar shapesCompare

HEPA ranks highest on insider conviction (92nd percentile) and risk and compliance (49th), and lowest on profitability (24th), among Pharma & Biotech peers.

Profitability
24
Inputs
  • Return on equity-125.6% · 27 pct, sector of 545
  • Return on assets-99.1% · 24 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-117.7% · 21 pct, sector of 576
Financial health
37
Inputs
  • Debt to equity0.14x · 50 pct, sector of 352
  • Cash flow to debt-9.03x · 24 pct, sector of 371
Insider conviction
92
Inputs
  • Net Form 4 buying (codes P and S), 180d$835K · 86 pct, sector of 428
  • Insider buyers, 180d6 · 97 pct, sector of 437
Risk and compliance
49
Inputs
  • Short interest, % of float+0.1% · 93 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+40.6% · 5 pct, sector of 511
3 not measured: Growth, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

HEPA filings, in plain words

Are Hepion Pharmaceuticals insiders buying or selling HEPA?

In the 180 days to 2026-10-28, Hepion Pharmaceuticals insiders were net buyers, a net $835.0K across purchases and sales reported on Form 4, by 6 buyers.

Read the full summary

In the 180 days to 2026-10-28, Hepion Pharmaceuticals insiders were net buyers of HEPA, a net $835.0K across purchases and sales reported on Form 4 by 6 buyers. 6 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 5 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 21.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies